Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer (SCLC) [1]. Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer cells [2]. In recent studies, lurbinectedin has been combined with immunotherapy drugs such as pembrolizumab to treat relapsed SCLC patients [2].

Although there is no direct evidence of any negative side effects of combining lurbinectedin and immunotherapy, it is important to note that both treatments have their own side effects. Lurbinectedin may cause nausea, vomiting, fatigue, anemia, and low white blood cell count [1]. Pembrolizumab, on the other hand, may cause fatigue, fever, chills, and diarrhea [2].

According to a study published in the Journal of Clinical Oncology, the combination of lurbinectedin and pembrolizumab showed promising preliminary activity in relapsed SCLC patients with an acceptable safety profile [3]. However, further studies are needed to evaluate the long-term safety and efficacy of this combination therapy.

In conclusion, while there is no direct evidence of negative side effects of combining lurbinectedin and immunotherapy, it is important to consider the potential side effects of each treatment individually. Patients should discuss the benefits and risks of this combination therapy with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancernetwork.com/view/antonio-calles-md-highlights-promising-preliminary-activity-of-lurbinectedin-and-pembrolizumab-in-relapsed-sclc
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/